Ayla Ellison

Fertility services—and conversations about them—are expanding across the U.S. But the sector remains underregulated, expensive and, in some cases, outdated.

After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration's import tariff policy for drugs.

Payers and providers felt the upheaval and instability on the Affordable Care Act exchanges in the first quarter of this year.

Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportu

Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product delivers short-term electrical nerve stimulation for chronic pain patients, for approximately $650 million in cash.

Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder and CEO of BioAge Labs.

Olympus has

It’s been more than two years since Eli Lilly announced LillyDirect, a platform that combines telehealth and pharmacy services to provide access to Lilly’s portfolio o

In the U.S., many top brand-name drugs continue to get more expensive with age, while the same medicines often get cheaper in peer countries, according to an AARP Public Policy Institute

Boston remains biotech's most influential hub, but the questions facing the region are increasingly global.